Nitrofurantoin (Macrobid) Should Be Avoided in Patients with eGFR <30 mL/min/1.73 m²
The FDA-approved drug label contraindications must be followed: nitrofurantoin is contraindicated when eGFR is <30 mL/min/1.73 m² and should not be initiated when eGFR is 30-60 mL/min/1.73 m² unless benefits clearly outweigh risks. 1
Current FDA Labeling and Guideline Recommendations
The FDA drug label does not provide explicit eGFR-based dosing adjustments but emphasizes that nitrofurantoin requires adequate renal function for therapeutic urinary concentrations 1. The KDOQI guidelines explicitly caution against using nitrofurantoin when GFR <60 mL/min/1.73 m² due to concerns about both reduced efficacy (inadequate urinary drug concentrations) and increased toxicity risk 2.
The 2011 IDSA/ESMID guidelines for uncomplicated cystitis recommend nitrofurantoin monohydrate/macrocrystals (100 mg twice daily for 5 days) as first-line therapy but do not specifically address renal function thresholds 3. More recent 2024 guidelines for UTI management recommend nitrofurantoin as a reasonable first-line choice for uncomplicated cystitis based on efficacy and low resistance rates 4.
Evidence-Based Thresholds by Renal Function
eGFR ≥60 mL/min/1.73 m²
- Safe and effective: Use standard dosing (100 mg twice daily for 5-7 days) 3, 4
- Clinical cure rates remain high (>80%) for most uropathogens 5, 6
- Nitrofurantoin remains first-line therapy at this level of function
eGFR 30-60 mL/min/1.73 m²
Controversial zone with conflicting evidence:
- The original contraindication at <60 mL/min was based on 1968 pharmacokinetic data showing reduced urinary drug recovery, but these studies had significant methodological limitations and did not measure clinical outcomes 7
- Recent observational data suggest nitrofurantoin may retain efficacy down to eGFR 30-40 mL/min for uncomplicated cystitis 7, 8, 5
- However, clinical failure rates increase progressively as eGFR declines below 60 mL/min 5, 6, 9
Practical approach for eGFR 40-60 mL/min: Consider nitrofurantoin if:
For eGFR 30-40 mL/min: Strongly prefer alternative agents (fosfomycin, trimethoprim-sulfamethoxazole if susceptible, or fluoroquinolones) as clinical cure rates with nitrofurantoin drop significantly in this range 5, 6
eGFR <30 mL/min/1.73 m²
- Contraindicated: Do not use 2, 1
- Inadequate urinary concentrations for efficacy
- Increased risk of systemic toxicity including pulmonary fibrosis with chronic use 10
- Alternative agents must be selected based on local resistance patterns
Organism-Specific Considerations
The effectiveness of nitrofurantoin varies significantly by pathogen and renal function:
- E. coli: Maintains ~89% susceptibility and reasonable efficacy down to eGFR 40-60 mL/min 6, 11, 12
- K. pneumoniae: Only 15% susceptibility; avoid nitrofurantoin regardless of renal function 11
- Gram-positive organisms: Require higher eGFR (approaching 100 mL/min) for 80% cure rates 9
Critical Safety Warnings
Pulmonary Toxicity Risk
Long-term or repeated nitrofurantoin use carries risk of irreversible pulmonary fibrosis, particularly in elderly patients and those with any degree of renal impairment 10. This risk exists even with eGFR >60 mL/min but increases with declining renal function. Patients should be counseled about respiratory symptoms (dyspnea, cough) and monitored accordingly.
Drug Interactions
- Avoid concomitant magnesium trisilicate antacids (reduces absorption) 1
- Uricosuric drugs (probenecid, sulfinpyrazone) increase serum levels and toxicity while decreasing urinary efficacy 1
Alternative Agents When Nitrofurantoin Is Inappropriate
For patients with eGFR <60 mL/min requiring UTI treatment:
Fosfomycin 3g single dose: Effective across all levels of renal function, including eGFR <30 mL/min; particularly effective when eGFR <60 mL/min compared to nitrofurantoin 6
Trimethoprim-sulfamethoxazole: Requires dose adjustment when eGFR <30 mL/min but remains an option if local resistance <20% 3, 4
Fluoroquinolones (ciprofloxacin, levofloxacin): Require 50% dose reduction when eGFR <15 mL/min; reserve for complicated infections due to collateral damage concerns 3, 2
Beta-lactams (cephalosporins): First-generation agents for pyelonephritis; ceftriaxone for IV therapy; various dose adjustments needed based on specific agent and eGFR 4
Summary Algorithm
For uncomplicated cystitis in women:
- eGFR ≥60: Nitrofurantoin 100 mg BID × 5 days (first-line)
- eGFR 40-60: Consider nitrofurantoin with close monitoring OR prefer fosfomycin 3g × 1 dose
- eGFR 30-40: Fosfomycin 3g × 1 dose preferred; avoid nitrofurantoin
- eGFR <30: Contraindicated; use fosfomycin or adjusted-dose alternatives based on susceptibility
For pyelonephritis or complicated UTI: Nitrofurantoin is not appropriate regardless of renal function; use systemic agents (fluoroquinolones, cephalosporins, or carbapenems based on severity and resistance patterns) 3, 4